Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-45. (canceled)

46. (Canceled)

47. (Currently amended) A compound ~~according to claim 46~~ having the formula



or a N-oxide form, a pharmaceutically acceptable addition salt and stereo-chemically isomeric form thereof, wherein[[;]]

n represents an integer being 0, 1, or 2;

m represents an integer being 1;

R^1 represents Ar^1, C_{1-4}alkyl, or C_{1-4}alkyl substituted with morpholinyl;

R^2 and R^3 taken together with the carbon atom to which they are attached form a C_{3-8}cycloalkyl or Het^1 wherein said C_{3-8}cycloalkyl or Het^1 each independently may optionally be substituted with C_{1-4}alkyloxycarbonyl;

R^4 represents halo or ~~R^4 represents~~ C_{1-4}alkyloxy;

R^5 represents C_{1-4}alkyloxycarbonyl, -O-(mono- or di(C_{1-4}alkyl)aminosulfonyl), C_{1-4}alkyl substituted with one or where possible more substituent being selected from Het^3 or NR^6R^7,

C_{1-4}alkyloxy substituted with one or where possible more substituents being selected from amino, Het^4 or NR^8R^9;

R^6 and R^7 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, Het^5 or C_{1-4}alkyl substituted with one or where possible more substituents being selected from hydroxy or Het^5;

R^8 and R^9 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, Het^7 or mono- or di(C_{1-4}alkyl)aminosulphonyl;

Het^1 represents piperidinyl;

Het^3 represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C_{1-4}alkyl, aminosulfonyl, amino, mono- or di(C_{1-4}alkyl)aminosulfonyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkyl or C_{1-4}alkyloxy;

Het^5 represents pyridinyl optionally substituted with mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^7 represents piperidinyl optionally substituted with C_{1-4}alkylphenyl, C_{1-4}alkyloxycarbonyl, or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Ar^1 represents an aryl substituent selected from phenyl or naphthalenyl;

48. (Currently amended) A compound according to claim [[46]] 47 wherein;

R^1 represents C_{1-4}alkyl;

R^2 and R^3 taken together with the carbon atom to which they are attached form a C_{3-8}cycloalkyl or piperidinyl wherein said C_{3-8}cycloalkyl or Het^1 each independently may optionally be substituted with C_{1-4}alkyloxycarbonyl;

R^4 represents halo or C_{1-4}alkyloxy;

R^5 represents C_{1-4}alkyloxycarbonyl, -O-(mono- or di(C_{1-4}alkyl)aminosulfonyl),

C_{1-4}alkyl substituted with one or where possible more substituent being selected from Het^3 or NR^6R^7,

C_{1-4}alkyloxy substituted with one or where possible more substituents being selected from amino, Het^4 or NR^8R^9;

R^6 and R^7 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, -Het^5 or C_{1-4}alkyl substituted with one or where possible more substituents being selected from hydroxy, or Het^5;

R^8 and R^9 are each independently selected from hydrogen, C_{1-4}alkyl, -Het^7 or mono- or di(C_{1-4}alkyl)aminosulphonyl;

Het^3 represents a heterocycle selected from piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, aminosulfonyl, amino, mono- or di(C_{1-4}alkyl)aminosulfonyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkyl or C_{1-4}alkyloxy;

Het^4 represents a heterocycle selected from morpholinyl, piperidinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^5 represents a heterocycle selected from pyridinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^7 represents piperidinyl.

49. (Currently amended) A compound as claimed in claim [[46]] 47, wherein R^2 and R^3 taken together with the carbon atom to which they are attached form a C_{3-8}cycloalkyl.

50. (Currently amended) A compound as claimed in claim [[49]] 47, wherein R^2 and R^3 taken together with the carbon atom to which they are attached are cyclopentyl.

51. (Canceled)

52. (Canceled)

53. (Canceled)

54. (Currently amended) A compound as claimed in claim [[46]] 47, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C_{1-4}alkyl substituent, or Het^4 consists of piperazinyl substituted with one mono- or di(C_{1-4}alkyl)aminosulfonyl substituent.

55. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective kinase inhibitory amount of a compound as described in claim [[46]] 47.

56. (Currently amended) A process of preparing a compound as described in claim [[46]] 47, comprising

i) reacting a primary amine of formula (V) with an aldehyde of formula (VI) wherein Q is



defined as

in a condensation reaction using ethanol as a suitable solvent;



e) EtOH

ii) followed by a nitrosative cyclisation of the thus obtained Schiffs bases of formula (II) with $NaNO_2$ in acetic acid, and refluxing the nitroso intermediates of formula (III) in a suitable solvent such as acetic anhydride or ethanol further comprising dithiothreitol (DTT);



a) $NaNO_2$, AcOH, H_2O b) DTT, EtOH

57. (Canceled)

58. (Currently amended) A compound as claimed claim [[57]] 49, wherein R^2 and R^3 taken together with the carbon atom to which they are attached form cyclopentyl.

59. (Currently amended) A compound according to claim [[46]] 47, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents C_{1-4}alkylsulfonyl or C_{1-4}alkylcarbonyl.

60. (Previously presented) A compound according to claim 59, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents methylsulfonyl or methylcarbonyl.

61. (Previously presented) A compound according to claim 60, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents methylsulfonyl.

62. (Previously presented) A compound according to claim 60, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents methylcarbonyl.

63. (Currently amended) A compound as claimed in claim [[46]] 47, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C_{1-4}alkyl substituent, or Het^4 consists of piperazinyl substituted with one mono- or di(C_{1-4}alkyl)aminosulfonyl substituent.

64. (Previously presented) A compound as claimed in claim 63, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R^5 substituent.

65. (Previously presented) A compound as claimed in claim 47, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R^5 substituent.

66. (Previously presented) A compound as claimed in claim 48, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R^5 substituent.

67. (Previously presented) A compound as claimed in claim 50, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of

morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with dimethylaminosulfonyl, in the para position relative to the carbon atom bearing the R^5 substituent.